Exane Derivatives’s Idexx Laboratories IDXX Stock Holding History

Exane Derivatives’s Portfolio IDXX Stock Details IDXX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-61	Closed	-$40.2K	–	1048
2021 Q4	$40.2K	Buy	+61	New	+$38.3K	0.01%	523

Other funds holding IDXX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Exane Derivatives's IDXX Position: Q1 2022 in Review

Exane Derivatives sold out of Idexx Laboratories (IDXX) in Q1 2022, closing a stake of 61 shares — an estimated $40.2K sold.

Exane Derivatives first reported a position in IDXX in Q4 2021 and held it in 1 quarter. The position peaked at $40.2K in Q4 2021. 1,032 funds tracked by Wall St. Rank hold IDXX as of Q1 2022.

Exane Derivatives reported no remaining Idexx Laboratories position as of Q1 2022 after selling out during the quarter.
Exane Derivatives sold 61 Idexx Laboratories shares in Q1 2022, an estimated $40.2K.
Exane Derivatives first reported a position in Idexx Laboratories in Q4 2021 and held it in 1 quarter.
Exane Derivatives's Idexx Laboratories position peaked at $40.2K in Q4 2021.
1,032 funds tracked by Wall St. Rank held Idexx Laboratories as of Q1 2022.

Based on Exane Derivatives's 13F filing for Q1 2022, filed 22 Apr 2022.